Product Description
Deflazacort is used to treat Duchenne muscular dystrophy (DMD; a progressive disease in which the muscles do not function properly) in adults and children 2 years of age and older. Deflazacort is in a class of medications called corticosteroids. It works by reducing inflammation (swelling) and by changing the way the immune system works. (Sourced from: https://medlineplus.gov/druginfo/meds/a617024.html)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Brazil | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | Germany | Greece | India | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Muscular Dystrophies | Muscular Dystrophy, Duchenne
Known Adverse Events: Hirsutism | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Obesity
Company: PTC Therapeutics
Company Location: SOUTH PLAINFIELD NJ 07080-2449
Company CEO: Stuart W. Peltz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: India
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Aspergillosis, Allergic Bronchopulmonary|Pulmonary Aspergillosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RA/2020/001 | P3 |
Active, not recruiting |
Pulmonary Aspergillosis|Aspergillosis, Allergic Bronchopulmonary |
2024-12-01 |